Tumor formation in the neonatal mouse bioassay indicates that the potent carcinogen dibenzo[def,p]chrysene (dibenzo[a,l]pyrene) is activated in vivo via its trans-11,12-dihydrodiol

Evaluation of the cancer risk from PAHs by inhalation: Are current methods fit for purpose?

There is ample evidence from occupational studies that exposure to a mixture of Polycyclic Aromatic Hydrocarbons (PAHs) is causally associated with an increased incidence of lung cancers. In both occupational atmospheres and ambient air, PAHs are present as a mixture of many compounds, but the composition of the mixture in ambient air differs from that in the occupational atmosphere, and varies in time and space in ambient air. Estimates of cancer risk for PAH mixtures are based upon unit risks which derive from extrapolation of occupational exposure data or animal model data, and in the case of the WHO use one compound, benzo[a]pyrene as a marker for the entire mixture, irrespective of composition. The U.S. EPA has used an animal exposure study to derive a unit risk for inhalation exposure to benzo[a]pyrene alone, and there have been a number of rankings of relative carcinogenic potency for other PAHs which many studies have used to calculate a cancer risk from the PAHs mixture, frequently incorrectly by adding the estimated relative risks of individual compounds, and applying the total "B[a]P equivalent" to the WHO unit risk, which already applies to the entire mixture. Such studies are often based upon data solely for the historic US EPA group of 16 compounds which do not include many of the apparently more potent carcinogens. There are no data for human cancer risk of individual PAHs, and conflicting evidence of additivity of PAH carcinogenicity in mixtures. This paper finds large divergences between risk estimates deriving from the WHO and U.S. EPA methods, as well as considerable sensitivity to the mixture composition, and assumed PAH relative potencies. Of the two methods, the WHO approach appears more likely to provide reliable risk estimates, but recently proposed mixture-based approaches using in vitro toxicity data may offer some advantages.

Translating dosimetry of Dibenzo[def,p]chrysene (DBC) and metabolites across dose and species using physiologically based pharmacokinetic (PBPK) modeling

Dibenzo[def,p]chrysene (DBC) is an environmental polycyclic aromatic hydrocarbon (PAH) that causes tumors in mice and has been classified as a probable human carcinogen by the International Agency for Research on Cancer. Animal toxicity studies often utilize higher doses than are found in relevant human exposures. Additionally, like many PAHs, DBC requires metabolic bioactivation to form the ultimate toxicant, and species differences in DBC and DBC metabolite metabolism have been observed. To understand the implications of dose and species differences, a physiologically based pharmacokinetic model (PBPK) for DBC and major metabolites was developed in mice and humans. Metabolism parameters used in the model were obtained from experimental in vitro metabolism assays using mice and human hepatic microsomes. PBPK model simulations were evaluated against mice dosed with 15 mg/kg DBC by oral gavage and human volunteers orally microdosed with 29 ng of DBC. DBC and its primary metabolite DBC-11,12-diol were measured in blood of mice and humans, while in urine, the majority of DBC metabolites were obeserved as conjugated DBC-11,12-diol, conjugated DBC tetrols, and unconjugated DBC tetrols. The PBPK model was able to predict the time course concentrations of DBC, DBC-11,12-diol, and other DBC metabolites in blood and urine of human volunteers and mice with reasonable accuracy. Agreement between model simulations and measured pharmacokinetic data in mice and human studies demonstrate the success and versatility of our model for interspecies extrapolation and applicability for different doses. Furthermore, our simulations show that internal dose metrics used for risk assessment do not necessarily scale allometrically, and that PBPK modeling provides a reliable approach to appropriately account for interspecies differences in metabolism and physiology.

Characterization of a multianalyte GC-MS/MS procedure for detecting and quantifying polycyclic aromatic hydrocarbons (PAHs) and PAH derivatives from air particulate matter for an improved risk assessment

A correct description of the concentration and distribution of particle bound polycyclic aromatic hydrocarbons is important for risk assessment of atmospheric particulate matter. A new targeted GC-MS/MS method was developed for analyzing 64 PAHs including compounds with a molecular weight >300, as well as nitro-, methyl-, oxy- and hydroxyl derivatives in a single analysis. The instrumental LOD ranged between 0.03 and 0.7 pg/μL for PAHs, 0.2-7.9 pg/μL for hydroxyl and oxy PAHs, 0.1-7.4 pg/μL for nitro PAHs and 0.06-0.3 pg/μL for methyl-PAHs. As an example for the relevance of this method samples of PM₁₀ were collected at six sampling sites in Medellin, Colombia, extracted and the concentration of 64 compounds was determined. The 16 PAHs from the EPA priority list contributed only from 54% to 69% to the sum of all analyzed compounds, PAH with high molecular weight accounted for 8.8%-18.9%. Benzo(a)pyrene equivalents (BaP_eq) were calculated for the estimation of the life time cancer (LCR). The LCR according to the samples ranged from 2.75 × 10^-5 to 1.4 × 10^-4 by a calculation with toxic equivalent factors (TEF) and 5.7 × 10^-5 to 3.8 × 10^-4 with potency equivalent factor (PEF). By using the new relative potency factors (RPF) recommended by US Environmental Protection Agency (U.S.EPA) the LCR ranged from 1.3 × 10^-4 to 7.2 × 10^-4. Hence, it was around six times higher than the well-known TEF. The novel method enables the reliable quantification of a more comprehensive set of PAHs bound on PM and thus will facilitate and improve the risk assessment of them.

Comparative Tumorigenicity and DNA Damage Induced by Dibenzo[ def,p]chrysene and Its Metabolites in the Mouse Ovary

Ovarian cancer ranked second in incidence among gynecologic cancers, but it causes more deaths than any other gynecologic cancer; at present there is no curative treatment beyond surgery. Animal models that employ carcinogens found in the human environment can provide a realistic platform to understand the mechanistic basis for disease development and to design rational chemopreventive/therapeutic strategies. We and others have shown that the administration of the environmental pollutant and tobacco smoke constituent dibenzo[ def,p]chrysene (DBP) to mice by several routes of exposure can induce tumors in multiple sites including the ovary. In the present study we compared, for the first time, the tumorigenicity and DNA damage induced by DBP and its metabolites DBP-dihydrodiol (DBPDHD) and DBP-dihydrodiol epoxide (DBPDE) in the mouse ovary. Compounds were dissolved in dimethyl sulfoxide (DMSO) as the vehicle and administered by topical application into the mouse oral cavity three times per week for 38 weeks. No tumors were observed in mice treated with DMSO. At equal dose (24 nmol/30 μL DMSO), the incidence of ovarian tumors induced by DBPDHD was higher (60.7%), although not significantly, than that induced by DBP (44.8%). Similarly the levels of DNA damage induced by DBPDHD in the ovary were higher than those observed with DBP. We did not observe any histological abnormality in the ovary of mice treated with DBPDE, which is consistent with lack of DNA damage. Our results suggested that both DBP and DBPDHD can be metabolized in the mouse ovary leading to the formation of DBPDE that can damage DNA, which is a prerequisite step in the initiation stage of carcinogenesis.

Tissue Distribution, Excretion and Pharmacokinetics of the Environmental Pollutant Dibenzo[def,p]chrysene in Mice

Dibenzo[def,p]chrysene (DBP), a representative example of the class of polycyclic aromatic hydrocarbon (PAH), is known to induce tumors in multiple organ sites including the ovary, lung, mammary glands, and oral cavity in rodents. The goal of this study was to test the hypothesis that the levels of DBP and its metabolites that reach and retain the levels for an extended time in the target organs as well as the capacity of these organs to metabolize this carcinogen to active metabolites that can damage DNA may account for its tissue selective tumorigenicity. Therefore, we used the radiolabeled [(3)H] DBP to accurately assess the tissue distribution, excretion, and pharmacokinetics of this carcinogen. We also compared the levels of DBPDE-DNA adducts in a select target organ (ovary) and nontarget organs (kidney and liver) in mice treated orally with DBP. Our results showed that after 1 week, 91.40 ± 7.23% of the radioactivity was recovered in the feces; the corresponding value excreted in the urine was less than 2% after 1 week. After 24 h, the stomach had the highest radioactivity followed by the intestine and the liver; however, after 1 week, levels of the radioactivity in these organs were the lowest among tissues examined including the ovary and liver; the pharmacokinetic analysis of DBP was conducted using a one compartment open model. The level of (-)-anti-trans-DBPDE-dA in the ovaries (8.91 ± 0.08 adducts/10(7) dA) was significantly higher (p < 0.01) than the levels of adducts in kidneys (0.69 ± 0.09 adducts/10(7) dA) and livers (0.63 ± 0.11 adducts/10(7) dA). Collectively, the results of the tissue distribution and pharmacokinetic analysis may not fully support our hypothesis, but the capacity of the target organs vs nontarget organs to metabolize DBP to active intermediates that can damage DNA may account for its tissue selective tumorigenicity.

Impact of pregnancy on the pharmacokinetics of dibenzo[def,p]chrysene in mice

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants generated during combustion. Dibenzo[def,p]chrysene (DBC) is a high molecular weight PAH classified as a 2B carcinogen by the International Agency for Research on Cancer. DBC crosses the placenta in exposed mice, causing carcinogenicity in offspring. We present pharmacokinetic data of DBC in pregnant and nonpregnant mice. Pregnant (gestational day 17) and nonpregnant female B6129SF1/J mice were exposed to 15mg/kg DBC by oral gavage. Subgroups of mice were sacrificed up to 48h postdosing, and blood, excreta, and tissues were analyzed for DBC and its major diol and tetrol metabolites. Elevated maximum concentrations and areas under the curve of DBC and its metabolites were observed in blood and tissues of pregnant animals compared with naïve mice. Using a physiologically based pharmacokinetic (PBPK) model, we found observed differences in pharmacokinetics could not be attributed solely to changes in tissue volumes and blood flows that occur during pregnancy. Measurement of enzyme activity in naïve and pregnant mice by activity-based protein profiling indicated a 2- to 10-fold reduction in activities of many of the enzymes relevant to PAH metabolism. Incorporating this reduction into the PBPK model improved model predictions. Concentrations of DBC in fetuses were one to two orders of magnitude below maternal blood concentrations, whereas metabolite concentrations closely resembled those observed in maternal blood.

Differential modulation of dibenzo[def,p]chrysene transplacental carcinogenesis: maternal diets rich in indole-3-carbinol versus sulforaphane

Cruciferous vegetable components have been documented to exhibit anticancer properties. Targets of action span multiple mechanisms deregulated during cancer progression, ranging from altered carcinogen metabolism to the restoration of epigenetic machinery. Furthermore, the developing fetus is highly susceptible to changes in nutritional status and to environmental toxicants. Thus, we have exploited a mouse model of transplacental carcinogenesis to assess the impact of maternal dietary supplementation on cancer risk in offspring. In this study, transplacental and lactational exposure to a maternal dose of 15mg/Kg B.W. of dibenzo[def,p]chrysene (DBC) resulted in significant morbidity of offspring due to an aggressive T-cell lymphoblastic lymphoma. As in previous studies, indole-3-carbinol (I3C, feed to the dam at 100, 500 or 1000ppm), derived from cruciferous vegetables, dose-dependently reduced lung tumor multiplicity and also increased offspring survival. Brussels sprout and broccoli sprout powders, selected for their relative abundance of I3C and the bioactive component sulforaphane (SFN), respectively, surprisingly enhanced DBC-induced morbidity and tumorigenesis when incorporated into the maternal diet at 10% wt/wt. Purified SFN, incorporated in the maternal diet at 400ppm, also decreased the latency of DBC-dependent morbidity. Interestingly, I3C abrogated the effect of SFN when the two purified compounds were administered in equimolar combination (500ppm I3C and 600ppm SFN). SFN metabolites measured in the plasma of neonates positively correlated with exposure levels via the maternal diet but not with offspring mortality. These findings provide justification for further study of the safety and bioactivity of cruciferous vegetable phytochemicals at supplemental concentrations during the perinatal period.

The role of estrogen receptor β in transplacental cancer prevention by indole-3-carbinol

In the present study, the efficacy of indole-3-carbinol (I3C), a key bioactive component of cruciferous vegetables, for prevention of cancer in offspring exposed in utero to the environmental carcinogen dibenzo[def,p]chrysene (DBC) was evaluated using an estrogen receptor β (ERβ) knockout mouse model. I3C was provided either through the maternal diet coincident with carcinogen exposure during pregnancy or directly to offspring postinitiation with DBC. I3C was effective at reducing T-cell acute lymphoblastic lymphoma/leukemia (T-ALL)-related mortality in offspring only if provided via the maternal diet, although a gender difference in the role of ERβ in mediating this response was evident. In female offspring, chemoprevention of T-ALL by maternal dietary I3C required expression of ERβ; survival in Esr2 wild-type and heterozygous female offspring was more than 90% compared with 66% in Esr2 null females. Alternatively, ERβ status did not significantly impact the transplacental chemoprevention by I3C in males. The possible role of ERβ in mediating lung carcinogenesis or chemoprevention by I3C was similarly complicated. Lung tumor incidence was unaltered by either dietary intervention, whereas lung tumor multiplicity was substantially reduced in Esr2 null females on the control diet and marginally lower in Esr2 null males exposed to I3C via the maternal diet compared with their wild-type and heterozygous counterparts. These findings suggest that I3C may act via ERβ to prevent or suppress DBC-initiated transplacental carcinogenesis but that the involvement of this receptor seems to differ depending on the cancer type and gender of the offspring.

Preliminary physiologically based pharmacokinetic models for benzo[a]pyrene and dibenzo[def,p]chrysene in rodents

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants generated as byproducts of natural and anthropogenic combustion processes. Despite significant public health concern, physiologically based pharmacokinetic (PBPK) modeling efforts for PAHs have so far been limited to naphthalene, plus simpler PK models for pyrene, nitropyrene, and benzo[a]pyrene (B[a]P). The dearth of published models is due in part to the high lipophilicity, low volatility, and myriad metabolic pathways for PAHs, all of which present analytical and experimental challenges. Our research efforts have focused upon experimental approaches and initial development of PBPK models for the prototypic PAH, B[a]P, and the more potent, albeit less studied transplacental carcinogen, dibenzo[def,p]chrysene (DBC). For both compounds, model compartments included arterial and venous blood, flow limited lung, liver, richly perfused and poorly perfused tissues, diffusion limited fat, and a two compartment theoretical gut (for oral exposures). Hepatic and pulmonary metabolism was described for both compounds, as were fractional binding in blood and fecal clearance. Partition coefficients for parent PAH along with their diol and tetraol metabolites were estimated using published algorithms and verified experimentally for the hydroxylated metabolites. The preliminary PBPK models were able to describe many, but not all, of the available data sets, comprising multiple routes of exposure (oral, intravenous) and nominal doses spanning several orders of magnitude.

Polycyclic aromatic hydrocarbons with molecular weight 302 in PM 2.5 at two industrial sites in South China

Daytime and nighttime PM(2.5) samples were collected between August 5 and 16, 2009 and between January 24 and February 4, 2010 in an industrial complex site (site A) and an electronic waste recycling site (site B) to determine the seasonal and diurnal variations of 19 individual polycyclic aromatic hydrocarbons (PAHs) with molecular weight 302 (MW302) including four highly carcinogenic dibenzopyrene (DBP) isomers dibenzo[a,l]pyrene (DBalP), dibenzo[a,e]pyrene (DBaeP), dibenzo[a,i]pyrene (DBaiP), and dibenzo[a,h]pyrene (DBahP). This is the first report on DBP isomers in air particles from South China. The total concentration of PAH MW302 isomers ranged from 1.65 to 3.60 ng m(-3) in summer and 3.82 to 9.81 ng m(-3) in winter. The strongest peaks in the chromatograms of the MW302 isomers were naphtha[2,1-a]pyrene (N21aP), dibenzo[j,l]fluoranthene (DBjlF), naphtha[1,2-b]fluoranthene (N12bF), naphtha[1,2-k]fluoranthene (N12kF) and dibenzo[a,e]fluoranthene (DBaeF), constituting 52.0 to 55.4% of the total MW302 isomers. All the MW302 isomers showed notable seasonal variations. Most of the MW302 isomers in site B showed distinctive diurnal variations with higher concentrations occurring in the night. Taking into account both concentration and potency equivalence factors (PEFs), the strongest carcinogen in the analyzed samples was DBaiP, and the ratios of sum carcinogenic potency of four highly carcinogenic DBP isomers to benzo[a]pyrene (BaP) was about 0.94 in winter to 1.89 in summer, indicating the importance of DBP isomers for the risk assessment. Health risk assessment indicated that on average, 1 in 100 000 residents in the two industrial sites may have an increased risk of cancer due to PAH exposure.

Determination of 252-302 Da and tentative identification of 316-376 Da polycyclic aromatic hydrocarbons in Standard Reference Materials 1649a Urban Dust and 1650b and 2975 Diesel Particulate Matter by accelerated solvent extraction-HPLC-GC-MS

We have assessed and compared the extraction recoveries of polycyclic aromatic hydrocarbons (PAHs) with molecular weights of 252, 276, 278, 300 and 302 from diesel particulate matter (PM) and urban air particles using ultrasonically assisted extraction and accelerated solvent extraction methods, and evaluated the effects of sample and treatment parameters. The results show that accelerated solvent extraction can extract PAHs more efficiently from diesel PM than ultrasonically assisted extraction. They also show that PAHs are more difficult to extract from diesel PM than from urban air particles. Using toluene and maximum instrumental settings (200 degrees C, 3,000 psi and five extraction cycles) with 30-min static extraction times > 85% of the analytes were estimated to be extracted from the diesel particles, but four extraction cycles with just 5-min static extraction times under these conditions seem to be sufficient to extract > 95% of the analytes from the urban air particles. The accelerated solvent extraction method was validated using the Standard Reference Materials (SRM) 1649a, Urban Dust, and SRM 2975 and SRM 1650a, Diesel Particulate Matter, from the US National Institute of Standards and Technology (NIST). PAH concentrations determined by on-line high-performance liquid chromatography-gas chromatography-mass spectrometry (HPLC-GC-MS) following the developed accelerated solvent extraction method were generally higher than the certified and reference NIST values and concentrations reported in the literature (e.g. the estimated concentration of benzo[a]pyrene in SRM 2975 was 15-fold higher than the NIST-certified value), probably because the extraction recoveries were higher than in previous studies. The developed accelerated solvent extraction method was used to analyse high molecular (HMW) weight PAHs (MW > 302) in the investigated SRMs, and more than 170 (SRM 1649a), 80 (SRM 1650b) and 60 (SRM 2975) potential high molecular weight PAHs were tentatively identified in them, with molecular weights (depending on the SRM sample analysed) of 316, 326, 328, 340, 342, 350, 352, 366, 374 and 376. This is, to our knowledge, the first study to tentatively report PAHs with molecular weights of 316, 326, 328, 342, 350, 352, 366 and 376 in diesel particulate matter. GC-MS chromatograms obtained in selected ion monitoring mode (extracted ions for the abovementioned m/z) and full-scan mass spectra of tentatively identified high molecular weight PAHs are shown in the Electronic supplementary material.

Identification and determination of highly carcinogenic dibenzopyrene isomers in air particulate samples from a street canyon, a rooftop, and a subway station in Stockholm

This study presents determined levels of the highly carcinogenic dibenzopyrene isomers dibenzo(a,l)pyrene, dibenzo(a,e)pyrene, dibenzo(a,l)pyrene, and dibenzo(a,h)pyrene as well as three other polycyclic aromatic hydrocarbons (PAHs)--benzo(a)pyrene, perylene and coronene--in ambient particulate material samples from a street canyon, a rooftop, and an underground subway station in Stockholm, Sweden. To our knowledge, these are the first reported determinations of dibenzopyrene isomers in air particles from either Stockholm or a subway station. Taking into account both concentration and toxic equivalence factors (TEFs), the PAH with the highest carcinogenic potency in the analyzed samples was dibenzo(a,l)pyrene, and the sum carcinogenic potency of the determined dibenzopyrenes was about 1-4 times higher than that of benzo(a)pyrene in the analyzed samples. These findings indicate that it is important to analyze the dibenzopyrene isomers as well as benzo(a)pyrene; the common approach of using benzo(a)pyrene as an indicator substance could lead to underestimates of the potential carcinogenic potency of PAHs in ambient air. The results also indicate that the relative carcinogenic potency of the determined dibenzopyrenes and benzo(a)pyrene in air particles from Stockholm is similar to that of air particles sampled in Washington in 1976-1977, despite general improvements in air quality in the intervening period. However, more data are needed to characterize temporal variations in dibenzopyrene levels in locations such as subway stations, suburbs, road tunnels, and metropolitan areas. There is also a need to identify and characterize both stationary and mobile PAH sources with respect to emission of dibenzopyrene isomers.

Determination of dibenzopyrenes in standard reference materials (SRM) 1649a, 1650, and 2975 using ultrasonically assisted extraction and LC-GC-MS

A method has been developed for analysis of the highly potent polycyclic aromatic hydrocarbon (PAH) carcinogens dibenzo(a,l)pyrene, dibenzo(a,h)pyrene, and dibenzo(a,i)pyrene (molecular weight 302) present in small amounts in diesel and air particulate material. The method can also be used for analysis of the PAH benzo(a)pyrene, coronene, and perylene, for which reference and certified values are available for the standard reference materials used for validation of the method--SRM 1649a (urban dust) and SRM 2975 (diesel particulate matter). The only NIST values that have been published for these dibenzopyrene isomers in the analyzed SRM are reference values for dibenzo(a,i)pyrene and dibenzo(a,h)pyrene in SRM 1649a. The concentrations determined in the SRM were in good agreement with reported NIST-certified and reference values and other concentrations reported in the literature. Standard reference material 1650 (diesel particulate matter) was also analyzed. The method could not, however, be validated using this material because certification of SRM 1650 had expired. The method is based on ultrasonically assisted extraction of the particulate material, then silica SPE pre-separation and isolation, and, separation and detection by hyphenated LC-GC-MS. The method is relatively rapid and requires only approximately 1-5 mg SRM particulate material to identify and quantify the analytes. Low extraction recoveries for the analytes, in particular the dibenzopyrenes, when extracting diesel SRM 2975 and 1650 resulted, however, in the dibenzopyrenes being present in amounts near their limits of quantifications in these samples. The method's limit of quantification (LOQ), based on analyses of SRM 1649a, is in the range 10-77 pg. By use of this method more than 25 potential PAH isomers with a molecular weight of 302 could be separated.